Clinical & Translational Oncology

Clinical & Translational Oncology英文簡(jiǎn)介

Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.

Clinical & Translational Oncology中文簡(jiǎn)介

《Clinical & Translational Oncology》是一本由SPRINGER INTERNATIONAL PUBLISHING AG出版商出版的專業(yè)醫(yī)學(xué)期刊，該刊創(chuàng)刊于2000年，刊期Monthly，該刊已被國(guó)際權(quán)威數(shù)據(jù)庫(kù)SCIE收錄。在中科院最新升級(jí)版分區(qū)表中，該刊分區(qū)信息為大類學(xué)科：醫(yī)學(xué) 3區(qū)，小類學(xué)科：腫瘤學(xué) 4區(qū)；在JCR（Journal Citation Reports）分區(qū)等級(jí)為Q3。該刊發(fā)文范圍涵蓋腫瘤學(xué)等領(lǐng)域，旨在及時(shí)、準(zhǔn)確、全面地報(bào)道國(guó)內(nèi)外腫瘤學(xué)工作者在該領(lǐng)域取得的最新研究成果、工作進(jìn)展及學(xué)術(shù)動(dòng)態(tài)、技術(shù)革新等，促進(jìn)學(xué)術(shù)交流，鼓勵(lì)學(xué)術(shù)創(chuàng)新。2021年影響因子為3.34，平均審稿速度平均2.2月。

中科院分區(qū)最新升級(jí)版（當(dāng)前數(shù)據(jù)版本：2021年12月最新升級(jí)版）

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)	Top期刊	綜述期刊
醫(yī)學(xué)	3區(qū)	ONCOLOGY 腫瘤學(xué)	4區(qū)	否	否

JCR分區(qū)（當(dāng)前數(shù)據(jù)版本：2021-2022年最新版）

JCR分區(qū)等級(jí)	JCR所屬學(xué)科	分區(qū)	影響因子
Q3	ONCOLOGY	Q3	3.34

期刊指數(shù)

影響因子	h-index	Gold OA文章占比	研究類文章占比	OA開放訪問	平均審稿速度
3.34	42	17.95%	82.44%	未開放	平均2.2月

IF值(影響因子)趨勢(shì)圖